• Disease
  • Chronic
  • Chronic Migraine
  • Joel R Saper

    Prominent publications by Joel R Saper

    KOL Index score: 19556

    OBJECTIVE: To assess the effectiveness of the nonprescription combination of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain.

    DESIGN: Three double-blind, randomized, parallel-group, single-dose, placebo-controlled studies.

    SETTING: Private practice, referral centers, and general community.

    PATIENTS: Migraineurs with moderate or severe headache pain who met International Headache Society diagnostic criteria for migraine with aura or without aura. The most ...

    Also Ranks for: Migraine Headache |  aspirin caffeine |  patients pain |  nonprescription combination |  nausea photophobia
    KOL Index score: 16693

    OBJECTIVE: To evaluate the efficacy and safety of topiramate (100 mg/day) compared with placebo for the treatment of chronic migraine.

    METHODS: This was a randomized, placebo-controlled, parallel-group, multicenter study consisting of 16 weeks of double-blind treatment. Subjects aged 18 to 65 years with 15 or more headache days per month, at least half of which were migraine/migrainous headaches, were randomized 1:1 to either topiramate 100 mg/day or placebo. An initial dose of ...

    Also Ranks for: Chronic Migraine |  placebo treatment |  safety topiramate |  100 day |  baseline monthly
    KOL Index score: 15961

    OBJECTIVE: To compare the efficacy and tolerability of sumatriptan nasal spray (NS; 5 mg, 10 mg, and 20 mg) with placebo for the treatment of acute migraine in adolescents.

    METHODS: A randomized, double-blind, placebo-controlled, single-attack study was conducted in 653 US adolescents (12-17 years of age). Patients with at least a 6-month history of migraine, who met International Headache Society criteria for migraine (with or without aura) were eligible for participation. Headache ...

    Also Ranks for: Acute Migraine |  headache relief |  20 placebo |  2 hours |  sumatriptan treatment
    KOL Index score: 15478

    OBJECTIVE: To assess the efficacy of tizanidine hydrochloride versus placebo as adjunctive prophylactic therapy for chronic daily headache (chronic migraine, migrainous headache, or tension-type headache).

    BACKGROUND: Tizanidine is an alpha2-adrenergic agonist that inhibits the release of norepinephrine at both the spinal cord and brain, with antinociceptive effects that are independent of the endogenous opioid system. Previous open-label studies have suggested the drug may be effective ...

    Also Ranks for: Chronic Daily Headache |  tizanidine placebo |  4 weeks |  tension type |  patients completed
    KOL Index score: 14785

    CONTEXT: Small open-label and controlled trials suggest that the antiepileptic drug topiramate is effective for migraine prevention.

    OBJECTIVE: To assess the efficacy and safety of topiramate for migraine prevention in a large controlled trial.

    DESIGN, SETTING, AND PATIENTS: A 26-week, randomized, double-blind, placebo-controlled study was conducted during outpatient treatment at 52 North American clinical centers. Patients were aged 12 to 65 years and had a 6-month history of migraine ...

    Also Ranks for: Migraine Prevention |  patients topiramate |  randomized controlled |  200 placebo |  responder rate
    KOL Index score: 14781

    BACKGROUND: The calcitonin gene-related peptide (CGRP) pathway is a promising target for preventive therapies in patients with migraine. We assessed the safety and efficacy of AMG 334, a fully human monoclonal antibody against the CGRP receptor, for migraine prevention.

    METHODS: In this multicentre, randomised, double-blind, placebo-controlled, phase 2 trial, patients aged 18-60 years with 4 to 14 migraine days per month were enrolled at 59 headache and clinical research centres in North ...

    Also Ranks for: Amg 334 |  episodic migraine |  2 trial |  monoclonal antibodies |  primary endpoint
    KOL Index score: 13785

    BACKGROUND: Preliminary work suggests that single-pulse transcranial magnetic stimulation (sTMS) could be effective as a treatment for migraine. We aimed to assess the efficacy and safety of a new portable sTMS device for acute treatment of migraine with aura.

    METHODS: We undertook a randomised, double-blind, parallel-group, two-phase, sham-controlled study at 18 centres in the USA. 267 adults aged 18-68 years were enrolled into phase one. All individuals had to meet international ...

    Also Ranks for: Acute Treatment |  migraine aura |  sham stimulation |  transcranial magnetic |  nausea photophobia
    KOL Index score: 13774

    OBJECTIVE: To compare gabapentin with placebo for use as a prophylactic agent in patients with migraine (with or without aura). STUDY DESIGN AND TREATMENT: After screening, a 4-week, single-blind, placebo baseline period was followed by a 12-week, double-blind, treatment period. The 12-week treatment period consisted of a 4-week titration phase and an 8-week stable-dosing phase. During the 4-week titration phase, patients were started on one 300-mg capsule of gabapentin or matching ...

    Also Ranks for: Patients Migraine |  gabapentin placebo |  4 week |  study medication |  treatment period
    KOL Index score: 13563

    OBJECTIVE: Currently, no drugs are Food and Drug Administration-approved for migraine prophylaxis in pediatric patients. The objective of this study was to evaluate the efficacy and safety of topiramate for migraine prevention in adolescents.

    METHODS: Adolescents (12-17 years of age) with a >/=6-month history of migraine were assigned randomly to receive 16 weeks of daily treatment with topiramate (50 or 100 mg/day) or placebo. The primary efficacy measure was the percent reduction in ...

    Also Ranks for: Migraine Prevention |  efficacy safety |  17 years |  50 day |  12 weeks
    KOL Index score: 12641

    OBJECTIVE: To evaluate the efficacy and safety of eptinezumab, a humanized anti-calcitonin gene-related peptide monoclonal antibody, in the preventive treatment of episodic migraine.

    METHODS: The PRevention Of Migraine via Intravenous ALD403 Safety and Efficacy-1 (PROMISE-1) study was a phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Adults with episodic migraine were randomized to eptinezumab 30 mg, 100 mg, 300 mg, or placebo for up to four ...

    Also Ranks for: Episodic Migraine |  eptinezumab 100 |  preventive treatment |  mmds weeks |  300 placebo
    KOL Index score: 12624

    OBJECTIVE: To determine if repetitive sphenopalatine ganglion (SPG) blocks with 0.5% bupivacaine delivered through the Tx360(®) are superior in reducing pain associated with chronic migraine (CM) compared with saline.

    BACKGROUND: The SPG is a small concentrated structure of neuronal tissue that resides within the pterygopalatine fossa (PPF) in close proximity to the sphenopalatine foramen and is innervated by the maxillary division of the trigeminal nerve. From an anatomical and ...

    Also Ranks for: Acute Treatment |  sphenopalatine ganglion |  bupivacaine saline |  spg blockade |  chronic migraine
    KOL Index score: 12339

    OBJECTIVE: The primary objective of this study was to compare the efficacy and tolerability of topiramate and amitriptyline in the prophylaxis of episodic migraine headache.

    METHODS: This was a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority study. Adults with 3 to 12 migraines per month were randomized in a 1:1 ratio to receive an initial dose of 25 mg/d of either topiramate or amitriptyline, subsequently titrated to a maximum of 100 mg/d (or ...

    Also Ranks for: Migraine Prevention |  topiramate amitriptyline |  life msq |  weight loss |  secondary outcome
    KOL Index score: 11739

    OBJECTIVE: This study assessed the efficacy of diclofenac potassium for oral solution, a novel water-soluble buffered powder formulation, versus placebo for the acute treatment of migraine. Diclofenac potassium for oral solution has a time to maximum plasma concentration (Tmax) of 15 minutes, suggesting the potential for a rapid onset of therapeutic effects.

    METHODS: This was a randomized, double-blind, parallel-group, placebo-controlled study conducted in 23 US centers. Adult sufferers ...

    Also Ranks for: Oral Solution |  acute treatment |  diclofenac potassium |  30 minutes |  headache pain nausea
    KOL Index score: 11484

    OBJECTIVE: To evaluate non-invasive vagus nerve stimulation (nVNS) as an acute cluster headache (CH) treatment.

    BACKGROUND: Many patients with CH experience excruciating attacks at a frequency that is not sufficiently addressed by current symptomatic treatments.

    METHODS: One hundred fifty subjects were enrolled and randomized (1:1) to receive nVNS or sham treatment for ≤1 month during a double-blind phase; completers could enter a 3-month nVNS open-label phase. The primary end point was ...

    Also Ranks for: Acute Treatment |  nvns sham |  cluster headache |  ech cch |  nerve stimulation
    KOL Index score: 11203

    OBJECTIVE: To assess the efficacy and tolerability of subcutaneous dihydroergotamine mesylate (DHE-45) vs subcutaneous sumatriptan succinate (Imitrex) for the treatment of acute migraine with or without aura.

    DESIGN: Double-blind, randomized trial with parallel treatment arms.

    SETTING: Clinics and private neurology practices.

    SUBJECTS: Patients of either sex, with migraine with or without aura, between the ages of 18 and 65 years.

    INTERVENTIONS: Patients with moderate or severe head pain ...

    Also Ranks for: Subcutaneous Dihydroergotamine |  acute migraine |  24 hours |  headache relief |  treated sumatriptan


    Joel R Saper: Influence Statistics

    Sample of concepts for which Joel R Saper is among the top experts in the world.
    Concept World rank
    open‐label dose‐titration #1
    ergotamine tartrate usage #1
    intractable cases consequence #1
    travis bickle #1
    growing staff #1
    reductions migraine #1
    recurrence treated headaches #1
    confronting behavioral #1
    mucate dichloralphenazone #1
    approaches overuse #1
    tizanidine effective prophylactic #1
    refractory daily headache #1
    tizanidine 4 weeks #1
    sodium propranolol #1
    intractability ways #1
    migraine distinct #1
    mildtomoderate migraine #1
    serotonin agonists ergots #1
    migraine overlap #1
    type secondary humans #1
    order behavioral barriers #1
    troubling encounters #1
    lithium migraine disorders #1
    phenomenon “migraine transformation #1
    topiramate 50 day #1
    average headache intensity #1
    isometheptene mucate #1
    opioid butalbital overuse #1
    saper meter #1
    behavioral therapy therapists #1
    migraine bms180048 #1
    3 hours dihydroergotamine #1
    pathogenetic mechanisms aspects #1
    study bms180048 #1
    assessment painful conditions #1
    geriatric headache #1
    patient galcanezumab #1
    55 headache #1
    treatment monitoring guide #1
    saper #1
    ways painful disorders #1

    Key People For Chronic Migraine

    Top KOLs in the world
    Richard B Lipton
    chronic migraine united states acute treatment
    Stephen David Silberstein
    chronic migraine cluster headache acute treatment
    David William Dodick
    chronic migraine cluster headache acute treatment
    Peter James Goadsby
    cluster headache chronic migraine acute treatment
    Hanschristoph C Diener
    atrial fibrillation cluster headache chronic migraine
    Marcelo Eduardo Bigal
    chronic migraine preventive treatment temporomandibular disorders

    Joel R Saper:Expert Impact

    Concepts for whichJoel R Saperhas direct influence:Chronic migraine,  Acute treatment,  Naproxen sodium,  Chronic daily headache,  Acute migraine,  Episodic migraine,  Migraine headache,  Oral solution.

    Joel R Saper:KOL impact

    Concepts related to the work of other authors for whichfor which Joel R Saper has influence:Chronic migraine,  Cluster headache,  Botulinum toxin,  Acute treatment,  Medication overuse.



    Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

    Michigan Head Pain and Neurological Institute, Ann Arbor, MI, USA. | Michigan Headache & Neurological Institute, Ann Arbor, MI, USA | Michigan Headache and Neurological Institute Ann Arbor MI | Michigan Head Pain and Neurological Institute, Ann Arbor